The US Food and Drug Administration (FDA) is preparing measures to accelerate market approvals for vaping products and nicotine pouches, according to a Wall Street Journal report. The agency plans to revise its 2021 premarket review rules to simplify scientific standards and shorten review times for non-combustible alternatives.
Addressing Application Backlogs and Illicit Markets
The regulatory shift aims to resolve years of administrative delays that have slowed product reviews for major tobacco operators, including Altria Group, Philip Morris International, and British American Tobacco. Altria’s NJOY division recently joined legal actions against the FDA over these extended review cycles.
Officials view faster authorizations as a way to displace illicit, non-compliant imports that have entered the domestic market. Expanding access to authorized products is intended to offer regulated alternatives to adult smokers looking to switch from combustible cigarettes.
An HHS spokesperson outlined the policy direction:
“The Trump administration is committed to keeping nicotine out of the hands of kids, getting counterfeit vaping products off the streets and providing safer alternatives for adults who want to quit smoking cigarettes.”
Industry Expansion and Public Health Concerns
The announcement follows the agency’s recent marketing authorization for three JUUL2 e-cigarette products. While the decision signals commercial growth for harm-reduction portfolios, public health groups and some lawmakers argue that easing review standards could lead to higher youth nicotine adoption, urging the FDA to prioritize market enforcement over faster approvals.
- Turkey Plans Digital ID Checks to Stop Underage Tobacco Sales - October 12, 2026
- Over One Million Never-Smokers Now Vape Regularly in Great Britain - October 12, 2026
- Pennsylvania Vape Directory Takes Effect Oct. 17: Rules and Fines - October 9, 2026